ASCLS eNewsBytes

• The FDA Just Approved a New Medication to Treat High Cholesterol August 11, 2026
  The U.S. Food and Drug Administration has approved Lipfendra, a new daily pill from Merck, for treating high cholesterol in adults. It is the first oral medication in the PCSK9 inhibitor class.
• Machine Learning Predicts Survival in Breast Cancer Bone Metastasis August 11, 2026
  Machine learning models effectively predicted survival outcomes and identified patients at higher risk of early death in those with breast cancer bone metastasis, based on a comprehensive retrospective analysis.
• Laboratory Basics for High-Consequence Infectious Diseases August 11, 2026
  Timely laboratory testing is essential for safely caring for patients with suspected high-consequence infectious diseases, including Ebola, Lassa fever, Marburg virus disease and Middle East respiratory syndrome.
• FDA Approves Tylenol with Naproxen OTC August 11, 2026
  The FDA has approved Tylenol with Naproxen, marking it as the first and only over-the-counter fixed-dose combination of acetaminophen and naproxen sodium.
• The Power of Genetic Testing August 11, 2026
  Genetic testing aids rare disease patients by providing early diagnoses, facilitating prompt treatment, and reducing irreversible damage. It also offers families insights into conditions, access to research, support networks, treatment options, and guidance for future family planning.